Record Results, a CEO Succession, and the Bronchiectasis Build
Electromed posts its 15th consecutive quarter of growth, expands payer coverage, and prepares for a leadership transition.
ELMD · Earnings Call · 2026-08-25
Record Financials and a Leadership Handoff
Electromed (ELMD) wrapped up fiscal 2026 with a record quarter that extends its streak to 15 consecutive quarters of year-over-year revenue and profit growth. “Net revenue for the fourth quarter was a record $19.4 million, up 12% versus the fourth quarter of last year.” — James Cunniff, CEO · 2026-08-25 Operating income rose 26% to $3.8 million, and diluted EPS hit a quarterly record of $0.39. The full-year picture is even more striking: revenue grew 15.3% to $73.8 million, operating income jumped 43.7%, and net income reached $11.3 million, or $1.30 per diluted share.
Amid this momentum, the company announced a significant leadership transition. CEO Jim Cunniff, who has led Electromed for the past three years, will retire in April 2027.
I have never been more confident in the strength of the organization or in its opportunities.
The board has initiated a succession process, and Cunniff will remain through the transition. For investors, the surprise is not the results—they've been consistently strong—but the timing of the departure, introducing a degree of execution uncertainty that the market will monitor closely.
Strategic Tailwinds: Payer Coverage, E-Prescribe, and the CHEST Guidelines
The quarter's operational highlights clustered around bronchiectasis patient access. The company ended the year with 87% of covered lives under contract, having executed 40 new payer contracts and expanded its network by more than 6 million lives. This builds directly on the covered lives gains highlighted in prior quarters—like the 2.9 million added in fiscal Q2 2025—and reflects the durability of its market-access engine.
Management also touted the Smart Order e-prescribe platform, which now handles over 45% of orders and ships them five days faster than fax-based submissions. The CMS administrative simplification rule, which mandates electronic order processing by May 2028, aligns perfectly with Electromed's existing capability. “Net revenues for Q4 grew 11.6% to $19.4 million, bringing net revenues for our full fiscal year 2026 to a record $73.8 million or 15.3% growth from $64 million last year.” — Brad Nagel, CFO · 2026-08-25 The e-prescribe push is also a recurring theme: on the Q2 2026 call, the company described it as a "big focus" and lauded its impact on prescription turnaround.
The pending CHEST guidelines for bronchiectasis management were a topic of optimism. Although not yet published, CEO Jim Cunniff said they will include airway clearance as a treatment pillar—positive for the category. This complements the company's Airway Clearance therapy, which remains central to the Triple Down on Bronchiectasis campaign and the newer "Treat Smart from the Start" initiative.
Financial Strength and Capital Allocation
The balance sheet is a pillar of the story. Electromed ended June 30 with $20.5 million in cash, no debt, and working capital of $45.1 million. That flexibility supports continued investment in the sales force and R&D while also enabling opportunistic share repurchases ($3.9 million in fiscal 2026). “We continue to think in terms of priorities with our cash—first derisking the business, second investing back into the business, and beyond that, looking for ways to add shareholder value, primarily through share repurchases.” — Brad Nagel, CFO · 2026-08-25
Operating leverage was evident across the income statement. Total revenue hit a record, while gross margin expanded slightly to 78.5% for the full year despite wage inflation and tariff-related headwinds. The company's ability to convert top-line growth into bottom-line gains is a clear competitive advantage.
What Changed and Why It Matters
The most salient change is the CEO retirement. It comes at a time when the company is executing well, but the lack of a named successor adds near-term uncertainty. On the Q1 2026 call (August 2025), the company emphasized its "thoughtful approach to adding sales reps" and its "secret sauce" of organic growth—both of which remain intact. Yet the market has already reacted to the succession news: the stock is down roughly 30% from its July peak, though still up double-digits on a 90-day basis.
Under the surface, the hospital channel declined 29% in Q4, but this is a known lumpiness—management called out the longer sales cycle and its continued "bullish" view of hospitals as a gateway to the home. Home care, the core engine, grew 15%, and the company added six direct sales representatives to reach 64, with plans to expand to 67 territories in fiscal 2027. Sales rep productivity exceeded its target range at $1,145,000 per rep, prompting management to raise the fiscal 2027 target to $1,050,000-$1,150,000.
In short, the underlying business remains on a strong trajectory: double-digit growth, expanding margins, and a growing addressable market. The resignation of a highly regarded CEO introduces a new variable, but Electromed's fundamentals and its deepening penetration of the bronchiectasis patient population suggest the story is far from over.